Literature DB >> 18790673

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.

Yu Liu1, Bin Zeng, Zhuohan Zhang, Yuan Zhang, Rongcun Yang.   

Abstract

Myeloid-derived suppressor cells (MDSCs) accumulate in tumor-bearing hosts and are associated with immune suppression. Here, we described high level of expression of B7-H1 (CD274), PD-1 (CD279) and CTLA4 (CD152) by Gr-1(+)CD11b(+) MDSCs obtained from both ascites and spleens of mice bearing the 1D8 ovarian carcinoma, whereas B7-DC (CD273), CD40 and CD86 were absent. In contrast, B7-H1, PD-1 and CTLA-4 expression was not detected on Gr-1(+)CD11b(+) cells from naive mice. Expression of B7-H1 by Gr-1(+)CD11b(+) cells from naive mice could be induced by co-culture with 1D8 ovarian carcinoma cells. Gr-1(+)CD11b(+) cells derived from 1D8 tumor-bearing mice markedly suppressed antigen-specific immune responses, whereas Gr-1(+)CD11b(+) cells from naive mice did not. siRNA-mediated knockdown of B7-H1 in Gr-1(+)CD11b(+) cells of 1D8 tumor-bearing mice alleviated suppression of antigen-specific immune responses. Suppression of antigen-specific immune responses via B7-H1 on Gr-1(+)CD11b(+) myeloid cells was mediated by CD4(+)CD25(+) Foxp3(+) T regulatory cells and required PD-1. Antibody blockade of either B7-H1 or PD-1 retarded the growth of 1D8 tumor in mice. This suggests that expression of B7-H1 on Gr-1(+)CD11b(+) myeloid cells triggered by the 1D8 mouse model of ovarian carcinoma suppresses antigen-specific immunity via interaction with PD-1 on CD4(+)CD25(+) Foxp3(+) regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790673     DOI: 10.1016/j.clim.2008.07.030

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  46 in total

1.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

2.  The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.

Authors:  Qiu-Xia Qu; Qin Huang; Yu Shen; Yi-Bei Zhu; Xue-Guang Zhang
Journal:  Tumour Biol       Date:  2015-11-06

Review 3.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

4.  Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Chao-Hung Lee
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

5.  Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.

Authors:  José Medina-Echeverz; Chi Ma; Austin G Duffy; Tobias Eggert; Nga Hawk; David E Kleiner; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Immunol Res       Date:  2015-01-30       Impact factor: 11.151

6.  Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Authors:  Güllü Görgün; Mehmet K Samur; Kristen B Cowens; Steven Paula; Giada Bianchi; Julie E Anderson; Randie E White; Ahaana Singh; Hiroto Ohguchi; Rikio Suzuki; Shohei Kikuchi; Takeshi Harada; Teru Hideshima; Yu-Tzu Tai; Jacob P Laubach; Noopur Raje; Florence Magrangeas; Stephane Minvielle; Herve Avet-Loiseau; Nikhil C Munshi; David M Dorfman; Paul G Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 7.  Cancer-associated myeloproliferation: old association, new therapeutic target.

Authors:  Ryan A Wilcox
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

8.  A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.

Authors:  Samuel T Haile; Lucas A Horn; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Res       Date:  2014-04-02       Impact factor: 11.151

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 10.  B7-h3 and its role in antitumor immunity.

Authors:  Martin Loos; Dennis M Hedderich; Helmut Friess; Jörg Kleeff
Journal:  Clin Dev Immunol       Date:  2010-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.